NAD boost to prevent Alzheimer's in Down syndrome
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study tests whether a supplement that boosts a natural substance called NAD (which helps cells work properly) can slow or stop memory loss in people with Down syndrome. You and your caregiver would visit a clinic for regular checkups and take the supplement daily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Down syndrome (confirmed by a genetic test or medical records).
- You are 18 years or older and have a caregiver or family member who knows you well and can check in with the study team.
- You are not pregnant and will not become pregnant in the next 6 months (if female).
- You do not have severe kidney problems, serious liver issues, or a recent heart event.
- You are able to walk (with or without a walker or cane) and have no known allergy to vitamin B3 (niacin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an investigational drug called donanemab can lower amyloid plaques in the brain to slow Alzheimer's disease in adults with Down syndrome. Participants must be 35–50, have elevated brain amyloid, and not have dementia yet.
This trial tests whether taking creatine and HMB supplements can improve muscle strength, reduce inflammation, and increase muscle mass in people with Down syndrome. It may help if you or your loved one can do basic physical tests like standing from a chair and do not have kidney disease or severe mobility issues.
This trial tests if levetiracetam, a seizure medication, can prevent seizures in adults with Down syndrome who also have Alzheimer's disease. It aims to help manage a common complication and improve quality of life.
This study tests whether a medicine called memantine (already used for memory problems) can help people with Down syndrome think and remember better. Researchers will try different doses to find what works best and is safest.
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
Hear when a new Down Syndrome (DS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.